by Agathe Masson | Dec 17, 2024 | NCD Case Studies, NCD Partnerships, News
Following the agreement on a new licensing model between the Medicines Patent Pool (MPP) & Novartis in collaboration with the ATOM Coalition, generic, quality-assured nilotinib is now available on NCDconnect! This initiative is crucial in making lifesaving...
by Agathe Masson | Dec 16, 2024 | NCD Solutions, News
Welcome to NCDconnect, your Digital Procurement Platform for essential medicines and medical devices against noncommunicable diseases (NCD). Signing up is straightforward, and this guide will help you complete the process with ease. For visual assistance, check out...
by Agathe Masson | Dec 13, 2024 | Access to Care, NCD Solutions, News
Every child deserves a fighting chance against cancer, regardless of where they are born. Yet, stark inequalities persist in access to pediatric oncology treatment, especially in low- and middle-income countries (LMICs). As purchasers responsible for securing...
by Agathe Masson | Dec 9, 2024 | Access to Care, NCD Solutions, News
Sickle Cell Disease (SCD) is a genetic blood disorder that affects millions of people worldwide. Between 2010 and 2050, an estimated 14 million babies will be affected globally, with the vast majority born in low- and middle-income countries (LMICs). This staggering...
by Agathe Masson | Dec 9, 2024 | Access to Care, NCD Policy, News
Access to essential treatments is a cornerstone of effective healthcare systems. Both brand-name medicines and generics play vital roles in ensuring that patients receive the care they need. While brand-name medicines are often associated with innovation and...
by Agathe Masson | Dec 9, 2024 | Access to Care, NCD Financing, News
Success in improving access to cancer care is not about a one-size-fits-all approach; it involves addressing unmet needs with high-impact actions. In its comprehensive white paper, Improving Access to Affordable and Sustainable Oncological Care in Africa, IQVIA...
